WallStreetZenWallStreetZen

NASDAQ: TRDA
Entrada Therapeutics Inc Stock Ownership - Who owns Entrada Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Entrada Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Kory James WentworthChief Financial Officer2025-04-0311,134$2.10
$23.38kBuy
Kory James WentworthChief Financial Officer2025-03-171,784$10.67
$19.04kSell
Dipal DoshiCEO2025-03-0317,566$11.68
$205.15kSell
Kory James WentworthChief Financial Officer2025-03-034,929$11.68
$57.57kSell
Nathan J. DowdenPresident COO2025-03-035,144$11.68
$60.08kSell
Natarajan SethuramanPresident Research Develop.2025-03-036,138$11.68
$71.69kSell
Mpm Bioventures 2014 LP10% Owner2024-12-1121,787$20.23
$440.75kSell
Mpm Bioventures 2018 LP10% Owner2024-12-1121,787$20.23
$440.75kSell
Mpm Bioventures 2014 LP10% Owner2024-12-1022,935$20.77
$476.36kSell
Mpm Bioventures 2018 LP10% Owner2024-12-1022,935$20.77
$476.36kSell

1 of 7

TRDA insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when TRDA insiders and whales buy or sell their stock.

TRDA Shareholders

What type of owners hold Entrada Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Baker Bros Advisors LP12.94%4,865,819$39.56MInstitution
Baker Bros Advisors LP11.97%4,501,658$36.60MInsider
Todd Foley11.77%4,425,784$35.98MInsider
5am Venture Management LLC11.73%4,408,379$35.84MInstitution
Mpm Asset Management LLC11.65%4,381,062$35.62MInstitution
Mpm Bioventures 2014 LP11.65%4,381,062$35.62MInsider
Mpm Bioventures 2018 LP11.65%4,381,062$35.62MInsider
Price T Rowe Associates Inc7.72%2,903,025$23.60MInstitution
Roche Holding Ltd7.48%2,813,525$22.87MInsider
Janus Henderson Group PLC5.53%2,080,367$16.91MInstitution

1 of 3

TRDA vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
TRDA54.23%45.77%Net SellingNet Selling
ARCT87.85%12.15%Net Selling
TSHA81.51%15.27%Net BuyingNet Selling
RIGL32.39%67.61%Net SellingNet Selling
HRTX49.06%50.94%
View Top Biotech Stocks

Entrada Therapeutics Stock Ownership FAQ

Who owns Entrada Therapeutics?

Entrada Therapeutics (NASDAQ: TRDA) is owned by 81.41% institutional shareholders, 68.71% Entrada Therapeutics insiders, and 0.00% retail investors. Baker Bros Advisors LP is the largest individual Entrada Therapeutics shareholder, owning 4.50M shares representing 11.97% of the company. Baker Bros Advisors LP's Entrada Therapeutics shares are currently valued at $35.79M.

If you're new to stock investing, here's how to buy Entrada Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.